Novartis Could Add To Its Hospital-Acquired Infection Portfolio With Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Proposed acquisition of NeuTec would give Novartis two Phase III therapies for its nosocomial arsenal.